BCL2 and non-Hodgkin lymphoma: Phillips and colleagues demonstrated that resistance to BCL-2 inhibition with venetoclax in non-Hodgkin's lymphoma cells could be overcome with co-treatment with A-1210477, resulting in synergy between these two drugs [39].